These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 25213022)
21. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. Iwamoto T; Bianchini G; Booser D; Qi Y; Coutant C; Shiang CY; Santarpia L; Matsuoka J; Hortobagyi GN; Symmans WF; Holmes FA; O'Shaughnessy J; Hellerstedt B; Pippen J; Andre F; Simon R; Pusztai L J Natl Cancer Inst; 2011 Feb; 103(3):264-72. PubMed ID: 21191116 [TBL] [Abstract][Full Text] [Related]
22. Identification of lncRNA NEAT1/miR-21/RRM2 axis as a novel biomarker in breast cancer. Quan D; Chen K; Zhang J; Guan Y; Yang D; Wu H; Wu S; Lv L J Cell Physiol; 2020 Apr; 235(4):3372-3381. PubMed ID: 31621912 [TBL] [Abstract][Full Text] [Related]
23. Prognostic and Immunological Potential of Ribonucleotide Reductase Subunits in Liver Cancer. Yin X; Jiang K; Zhou Z; Yu H; Yan D; He X; Yan S Oxid Med Cell Longev; 2023; 2023():3878796. PubMed ID: 36713030 [TBL] [Abstract][Full Text] [Related]
24. Overexpression of catalytic subunit M2 in patients with ovarian cancer. Wang LM; Lu FF; Zhang SY; Yao RY; Xing XM; Wei ZM Chin Med J (Engl); 2012 Jun; 125(12):2151-6. PubMed ID: 22884145 [TBL] [Abstract][Full Text] [Related]
25. Inhibiting RRM2 to enhance the anticancer activity of chemotherapy. Zhan Y; Jiang L; Jin X; Ying S; Wu Z; Wang L; Yu W; Tong J; Zhang L; Lou Y; Qiu Y Biomed Pharmacother; 2021 Jan; 133():110996. PubMed ID: 33227712 [TBL] [Abstract][Full Text] [Related]
26. Autophagy induction causes a synthetic lethal sensitization to ribonucleotide reductase inhibition in breast cancer cells. Chen YR; Tsou B; Hu S; Ma H; Liu X; Yen Y; Ann DK Oncotarget; 2016 Jan; 7(2):1984-99. PubMed ID: 26675256 [TBL] [Abstract][Full Text] [Related]
27. CREB1 directly activates the transcription of ribonucleotide reductase small subunit M2 and promotes the aggressiveness of human colorectal cancer. Fang Z; Lin A; Chen J; Zhang X; Liu H; Li H; Hu Y; Zhang X; Zhang J; Qiu L; Mei L; Shao J; Chen X Oncotarget; 2016 Nov; 7(47):78055-78068. PubMed ID: 27801665 [TBL] [Abstract][Full Text] [Related]
28. Prognostic and therapeutic value of mitochondrial serine hydroxyl-methyltransferase 2 as a breast cancer biomarker. Zhang L; Chen Z; Xue D; Zhang Q; Liu X; Luh F; Hong L; Zhang H; Pan F; Liu Y; Chu P; Zheng S; Lou G; Yen Y Oncol Rep; 2016 Nov; 36(5):2489-2500. PubMed ID: 27666119 [TBL] [Abstract][Full Text] [Related]
29. E2F1 promote the aggressiveness of human colorectal cancer by activating the ribonucleotide reductase small subunit M2. Fang Z; Gong C; Liu H; Zhang X; Mei L; Song M; Qiu L; Luo S; Zhu Z; Zhang R; Gu H; Chen X Biochem Biophys Res Commun; 2015 Aug; 464(2):407-15. PubMed ID: 26093293 [TBL] [Abstract][Full Text] [Related]
30. Network-based approach to identify prognostic biomarkers for estrogen receptor-positive breast cancer treatment with tamoxifen. Liu R; Guo CX; Zhou HH Cancer Biol Ther; 2015; 16(2):317-24. PubMed ID: 25756514 [TBL] [Abstract][Full Text] [Related]
31. Potential mechanism of RRM2 for promoting Cervical Cancer based on weighted gene co-expression network analysis. Wang J; Yi Y; Chen Y; Xiong Y; Zhang W Int J Med Sci; 2020; 17(15):2362-2372. PubMed ID: 32922202 [TBL] [Abstract][Full Text] [Related]
32. Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response. Zhang YW; Jones TL; Martin SE; Caplen NJ; Pommier Y J Biol Chem; 2009 Jul; 284(27):18085-95. PubMed ID: 19416980 [TBL] [Abstract][Full Text] [Related]
33. Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer. Wilson EA; Sultana N; Shah KN; Elford HL; Faridi JS Mol Cancer Ther; 2021 Apr; 20(4):655-664. PubMed ID: 33536192 [TBL] [Abstract][Full Text] [Related]
34. Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells. Yang PM; Lin LS; Liu TP Biomolecules; 2020 Jan; 10(1):. PubMed ID: 31936661 [TBL] [Abstract][Full Text] [Related]
35. Identification of ribonucleotide reductase M2 as a potential target for pro-senescence therapy in epithelial ovarian cancer. Aird KM; Li H; Xin F; Konstantinopoulos PA; Zhang R Cell Cycle; 2014; 13(2):199-207. PubMed ID: 24200970 [TBL] [Abstract][Full Text] [Related]
36. High RRM2 expression has poor prognosis in specific types of breast cancer. Shi SC; Zhang Y; Wang T PLoS One; 2022; 17(3):e0265195. PubMed ID: 35290409 [TBL] [Abstract][Full Text] [Related]
37. The expression of ribonucleotide reductase M2 in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients. Su YF; Wu TF; Ko JL; Tsai HT; Tee YT; Chien MH; Chou CH; Lin WL; Low HY; Chou MY; Yang SF; Wang PH PLoS One; 2014; 9(3):e91644. PubMed ID: 24637958 [TBL] [Abstract][Full Text] [Related]
38. Genes responsive to both oxidant stress and loss of estrogen receptor function identify a poor prognosis group of estrogen receptor positive primary breast cancers. Yau C; Benz CC Breast Cancer Res; 2008; 10(4):R61. PubMed ID: 18631401 [TBL] [Abstract][Full Text] [Related]
39. Emerging roles of the ribonucleotide reductase M2 in colorectal cancer and ultraviolet-induced DNA damage repair. Lu AG; Feng H; Wang PX; Han DP; Chen XH; Zheng MH World J Gastroenterol; 2012 Sep; 18(34):4704-13. PubMed ID: 23002339 [TBL] [Abstract][Full Text] [Related]
40. Targeting ribonucleotide reductase M2 subunit by small interfering RNA exerts anti-oncogenic effects in gastric adenocarcinoma. Kang W; Tong JH; Chan AW; Zhao J; Wang S; Dong Y; Sin FM; Yeung S; Cheng AS; Yu J; To K Oncol Rep; 2014 Jun; 31(6):2579-86. PubMed ID: 24756820 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]